Abstracts

1088 – Impact of Rapid HIV Testing and Self-Testing on Lenacapavir Effectiveness and Resistance in Thailand

Background The World Health Organization (WHO) recommends twice-yearly lenacapavir as long-acting pre-exposure prophylaxis (PrEP), offering an alternative to oral PrEP. WHO advises using rapid and self-administered HIV tests with long-acting PrEP and emphasizes flexible testing to avoid limiting access. Rapid tests have reduced sensitivity, particularly during the acute stage of infection. Starting lenacapavir during undiagnosed…

635 – Structural Deletions in HTLV-1 Proviruses Correlate With Disease Severity in Adult T-Cell Leukemia

Background HTLV-1 is a neglected retrovirus associated with severe neurological and lymphoproliferative diseases, including tropical spastic paraparesis/HTLV-1-associated myelopathy (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL). Although Spain is a non-endemic country, more than 550 individuals with HTLV-1 infection had been reported up to date. A national HTLV-1 registry has existed since 1989. Most cases are migrants…

379 – BCL6 Enhances Tfh Cells Susceptible to HIV Infection by Dampening Intrinsic Antiviral Machineries

Background Lymph nodes (LNs) are a sanctuary for the HIV reservoir. Although the role of follicular helper T cells (Tfh) to the HIV reservoir during antiretroviral treatment (ART) remains debated, it is well-known that Tfh cells are highly susceptible to infection before ART initiation. The mechanisms underlying this susceptibility to infection are unknown and could…

489 – Clinical Accuracy of an Enzymatic Reverse Transcriptase Test for Monitoring Antiretroviral Adherence

Background Accurate and rapid objective tools are needed to detect non-adherence to daily oral HIV regimens and support timely transitions to long-acting injectables. RESTRICT is an HIV reverse transcriptase inhibition assay that has been calibrated to estimate tenofovir diphosphate (TFV-DP) concentrations in whole blood. We evaluated the clinical accuracy of RESTRICT compared with liquid chromatography–tandem…

584 – Mechanisms of HIV-Infected Cell Persistence Following Exposure to HIV Protease Activators

Background Despite effective antiretroviral therapy, the persistent viral reservoir remains a major challenge to achieving HIV cure. HIV protease activators (HPAs), a distinct group of non-nucleoside reverse transcriptase inhibitors, drive Gag-Pol dimerization and premature protease activation in infected cells. This unrestrained protease activity cleaves host proteins including CARD8, triggering inflammasome formation, caspase-1 activation, and pyroptotic…

1108 – Retention Trajectories in HIV Care Are Partially Patterned by Chronic Comorbidities in North America

Background Sustained retention in HIV care is critical for viral suppression and epidemic control, yet sources of heterogeneity in longitudinal care engagement, like clinical complexity and chronic comorbidity management, remain underexplored. Using a standard retention metric, we employed latent class analysis to describe retention trajectories and associated clinical profiles among people with HIV (PWH) in…